Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$438 Mln
Revenue (TTM)
$85 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
-3.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$8.7
EPS
$-2.4
Face value
--
Shares outstanding
51,051,487
CFO
$-327.25 Mln
EBITDA
$-396.64 Mln
Net Profit
$-400.46 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
4D Molecular Therapeutics Inc (FDMT)
| 26.4 | -1.9 | 26.4 | 217.1 | -18.0 | -25.0 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
4D Molecular Therapeutics Inc (FDMT)
| 34.6 | -72.2 | -8.8 | 1.2 | -47.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
4D Molecular Therapeutics Inc (FDMT)
|
9.5 | 437.5 | 85.2 | -140.1 | -187.2 | -27.6 | -- | 0.9 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United... States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California. Address: 5858 Horton Street, EmeryVille, CA, United States, 94608 Read more
Executive Chairman
Dr. John F. Milligan Ph.D.
Executive Chairman
Dr. John F. Milligan Ph.D.
Headquarters
EmeryVille, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of 4D Molecular Therapeutics Inc (FDMT) is $9.48 (NASDAQ) as of 02-Apr-2026 16:00 EDT. 4D Molecular Therapeutics Inc (FDMT) has given a return of -17.99% in the last 3 years.
Since, TTM earnings of 4D Molecular Therapeutics Inc (FDMT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-3.10
|
0.86
|
|
2024
|
-1.87
|
0.59
|
|
2023
|
-7.84
|
2.57
|
|
2022
|
-7.03
|
3.07
|
|
2021
|
-8.99
|
1.93
|
The 52-week high and low of 4D Molecular Therapeutics Inc (FDMT) are Rs 12.34 and Rs 2.24 as of 05-Apr-2026.
4D Molecular Therapeutics Inc (FDMT) has a market capitalisation of $ 438 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in 4D Molecular Therapeutics Inc (FDMT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.39
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.